Lesson plan
Relutrigine
Relutrigine ( ; developmental code name PRAX-562) is a persistent neuronal sodium channel blocker which is under development for the treatment of epilepsy and headache. It is taken orally. The drug shows anticonvulsant effects in animals but with improved tolerability compared to existing sodium channel blockers. Relutrigine is under development by Praxis Precision Medicines. As of May 2026, it is in preregistration for epilepsy. Conversely, no recent development has been reported for headaches.
Article summary
Relutrigine ( ; developmental code name PRAX-562) is a persistent neuronal sodium channel blocker which is under development for the treatment of epilepsy and headache. It is taken orally. The drug shows anticonvulsant effects in animals but with improved tolerability compared to existing sodium channel blockers. Relutrigine is under development by Praxis Precision Medicines. As of May 2026, it is in preregistration for epilepsy. Conversely, no recent development has been reported for headaches.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.